Supplementary materials: Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients

These are peer-reviewed supplementary materials for the article 'Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients' published in the Journal of Comparative Effectiveness Research.Table A1: ICD-10-CM codes for chronic PTSDTable A2: ICD-10 CM codes for acute PTSDTable A3: ICD-10-CM codes related to cancer diagnosisTable A4: ICD-10-CM codes related to MDD, bipolar disorder, and schizophreniaTable A5: NDC codes related to FDA-approved medications for PTSD treatmentTable A6: Procedure codes related to the psychotherapies used for PTSD managementTable A7: ICD-10-CM codes related to anxietyTable A8: Demographic characteristics of the matched populationTable A9: Clinical characteristics of the matched populationTable A10: Out-of-pocket healthcare costs of PTSD patients during the 2-year follow-up period within the matched populationTable A11: Overall healthcare costs of PTSD patients during the 2-year follow-up period within the matched populationTable A12: The resource use of PTSD patients during the first year of the follow-up period within the matched populationTable A13: Demographic characteristics of PTSD patients with SUD/AUD diagnosisTable A14: Clinical characteristics of PTSD patients with SUD/AUD diagnosisTable A15: Out-of-pocket healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUDTable A16: Overall healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUDTable A17: Resource use during the first year of the follow-up period within the sub-sample of chronic PTSD patients diagnosed with SUD/AUDAim: Exploring the healthcare costs and resource use among privately insured US patients with posttraumatic stress disorder (PTSD). Methods: This study used Merative MarketScan data. The index date was defined as the first PTSD claim. Study period included a 1-year pre-index and 2-year post-index follow-up. Cases with only acute PTSD, cancer, or insurance gap during the study period were excluded. The PTSD with (PwC) and PTSD without comorbidities (PwoC) cohorts were defined by the presence/absence of comorbid mental health conditions (schizophrenia, bipolar and major depressive disorder). Baseline PTSD (BP) cohort included PwoC cases with only index PTSD event and without FDA-approved PTSDmedications or psychotherapy. Sub-analysis is conducted among patients with PTSD and substance/alcohol use disorder. Study cohorts were matched in a 1:1:1 ratio. Results: The matched sample included 5076 patients (1681 PwC, 1681 PwoC, 1714 BP). PwC patients had higher 2-year PTSD-related costs than PwoC and BP patients ($3762 vs $1750 and $841; all p Conclusion: PTSD is associated with high healthcare costs and resource use. The highest economic burden was observed in patients with PTSD and mental health comorbidities.